CN102596923B - 1,2,4-噻唑烷-3-酮衍生物及其在癌症治疗中的用途 - Google Patents
1,2,4-噻唑烷-3-酮衍生物及其在癌症治疗中的用途 Download PDFInfo
- Publication number
- CN102596923B CN102596923B CN201080030894.9A CN201080030894A CN102596923B CN 102596923 B CN102596923 B CN 102596923B CN 201080030894 A CN201080030894 A CN 201080030894A CN 102596923 B CN102596923 B CN 102596923B
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- methyl
- thiadiazol
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *C=CCNC(N(*C(**=**)=I)C(N)=O)=S Chemical compound *C=CCNC(N(*C(**=**)=I)C(N)=O)=S 0.000 description 3
- JWCZVGWBEPZJLO-UHFFFAOYSA-N COc(cc1)ccc1C(NC(SN1Cc(cc2)ccc2F)=NC1=O)=O Chemical compound COc(cc1)ccc1C(NC(SN1Cc(cc2)ccc2F)=NC1=O)=O JWCZVGWBEPZJLO-UHFFFAOYSA-N 0.000 description 1
- TZSKWUDSKVQLKM-SILNSSARSA-N O=C(c(cc1Cl)ccc1Cl)/N=C(/N1Cc(cc2)ccc2F)\SNC1=O Chemical compound O=C(c(cc1Cl)ccc1Cl)/N=C(/N1Cc(cc2)ccc2F)\SNC1=O TZSKWUDSKVQLKM-SILNSSARSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21373509P | 2009-07-08 | 2009-07-08 | |
| US61/213735 | 2009-07-08 | ||
| PCT/GB2010/001315 WO2011004162A2 (en) | 2009-07-08 | 2010-07-08 | Compounds useful as medicaments |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102596923A CN102596923A (zh) | 2012-07-18 |
| CN102596923B true CN102596923B (zh) | 2015-04-29 |
Family
ID=43086401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080030894.9A Active CN102596923B (zh) | 2009-07-08 | 2010-07-08 | 1,2,4-噻唑烷-3-酮衍生物及其在癌症治疗中的用途 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9162994B2 (enExample) |
| EP (1) | EP2451794B1 (enExample) |
| JP (1) | JP5982281B2 (enExample) |
| KR (1) | KR101765957B1 (enExample) |
| CN (1) | CN102596923B (enExample) |
| AU (1) | AU2010270030B2 (enExample) |
| BR (1) | BR112012000370B1 (enExample) |
| CA (1) | CA2767291C (enExample) |
| DK (1) | DK2451794T3 (enExample) |
| EA (1) | EA026674B1 (enExample) |
| ES (1) | ES2567753T3 (enExample) |
| HR (1) | HRP20160353T1 (enExample) |
| HU (1) | HUE027263T2 (enExample) |
| IL (1) | IL216723A (enExample) |
| ME (1) | ME02443B (enExample) |
| MX (1) | MX337516B (enExample) |
| NZ (1) | NZ597075A (enExample) |
| PL (1) | PL2451794T3 (enExample) |
| RS (1) | RS54718B1 (enExample) |
| SG (1) | SG177558A1 (enExample) |
| SI (1) | SI2451794T1 (enExample) |
| SM (1) | SMT201600225B (enExample) |
| WO (1) | WO2011004162A2 (enExample) |
| ZA (1) | ZA201108901B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100931145B1 (ko) * | 2008-07-04 | 2009-12-10 | 현대자동차주식회사 | 조정식 킥 다운 스위치의 조작기구 |
| WO2013108026A1 (en) | 2012-01-17 | 2013-07-25 | Baltic Bio Ab | Thiadiazolone derivatives useful in the treatment of diabetes |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| CA2905242C (en) | 2013-03-15 | 2016-11-29 | Pfizer Inc. | Indole compounds that activate ampk |
| GB201308325D0 (en) * | 2013-05-09 | 2013-06-19 | Immodulon Therapeutics Ltd | Cancer Therapy |
| US10774064B2 (en) | 2016-06-02 | 2020-09-15 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| CN114539273A (zh) | 2016-06-07 | 2022-05-27 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
| CU24560B1 (es) | 2017-01-23 | 2021-12-08 | Cadent Therapeutics Inc | N-(4,4-difluorociclohexil)-2-(3-metil-1h-pirazol-1-il)-6-morfolinopirimidin-4-amina útil como modulador de canales de potasio |
| HRP20241239T1 (hr) | 2017-03-23 | 2024-12-06 | Jacobio Pharmaceuticals Co., Ltd. | Novi heterociklički derivati korisni kao shp2 inhibitori |
| WO2020063760A1 (en) | 2018-09-26 | 2020-04-02 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
| AU2019366312B2 (en) | 2018-10-22 | 2025-04-24 | Novartis Ag | Crystalline forms of potassium channel modulators |
| WO2020095010A1 (en) | 2018-11-05 | 2020-05-14 | Balticgruppen Bio Ab | Methods of treating diabetes in severe insulin-resistant diabetic subjects |
| CN109879808B (zh) * | 2019-03-05 | 2020-10-16 | 北京工业大学 | 一种含五元唑类杂环基查尔酮类衍生物及制备方法和医药用途 |
| GB201910093D0 (en) | 2019-07-15 | 2019-08-28 | Balticgruppen Bio Ab | New formulations |
| GB201910092D0 (en) | 2019-07-15 | 2019-08-28 | Balticgruppen Bio Ab | New formulations |
| GB201915094D0 (en) * | 2019-10-18 | 2019-12-04 | Balticgruppen Bio Ab | New formulations |
| US11691954B2 (en) | 2019-10-18 | 2023-07-04 | Betagenon Ab | Formulations |
| GB202015585D0 (en) * | 2020-10-01 | 2020-11-18 | Betagenon Bio Ab | New compounds |
| GB202100352D0 (en) | 2021-01-12 | 2021-02-24 | Balticgruppen Bio Ab | New methods |
| GB202112529D0 (en) | 2021-09-02 | 2021-10-20 | Betagenon Bio Ab | New compounds |
| WO2025017193A1 (en) | 2023-07-20 | 2025-01-23 | Betagenon Ab | Methods of treating cardiomyopathy induced by metabolic inflexibility |
| WO2025017194A1 (en) | 2023-07-20 | 2025-01-23 | Betagenon Ab | Methods for regulating blood glucose levels using a dual ampk activator and mitochondrial uncoupler |
| WO2025027205A1 (en) | 2023-08-03 | 2025-02-06 | Betagenon Ab | Treatment of cancer with the pdk inhibitor 4-chloro-n-(2-(4-chlorobenzyl)-3-oxo-2,3-dihydro-1,2,4-thiadiazol-5-yl)benzamide |
| WO2025252672A1 (en) | 2024-06-03 | 2025-12-11 | Betagenon Ab | Use of tryptophan and metabolites thereof as biomarkers for treatment methods |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006045581A1 (en) * | 2004-10-21 | 2006-05-04 | Neuropharma, S.A. | The use of 1, 2, 4-thiadiazolidine-3, 5-diones as ppar activators |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4093624A (en) | 1977-01-31 | 1978-06-06 | Icn Pharmaceuticals, Inc. | 1,2,4-Thiadiazolidine-3,5-dione |
| ES2166328B1 (es) * | 2000-05-11 | 2003-09-16 | Consejo Superior Investigacion | Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos |
| HUP0302002A3 (en) | 2000-05-11 | 2007-02-28 | Consejo Superior Investigacion | Heterocyclic inhibitors of glycogen synthase kinase gsk-3, their use and pharmaceutical compositions containing them |
| KR20080034436A (ko) | 2005-07-21 | 2008-04-21 | 베타게논 에이비 | 암 치료에 사용되는 티아졸 유도체 및 유사체 |
| WO2008090356A1 (en) | 2007-01-25 | 2008-07-31 | Betagenon Ab | Thiazolidinone derivatives useful in the treatment of cancer and disorders caused by excess adiposity |
-
2010
- 2010-07-08 WO PCT/GB2010/001315 patent/WO2011004162A2/en not_active Ceased
- 2010-07-08 KR KR1020117030830A patent/KR101765957B1/ko active Active
- 2010-07-08 ES ES10759940.9T patent/ES2567753T3/es active Active
- 2010-07-08 HR HRP20160353TT patent/HRP20160353T1/hr unknown
- 2010-07-08 JP JP2012519055A patent/JP5982281B2/ja active Active
- 2010-07-08 EP EP10759940.9A patent/EP2451794B1/en active Active
- 2010-07-08 MX MX2012000441A patent/MX337516B/es active IP Right Grant
- 2010-07-08 DK DK10759940.9T patent/DK2451794T3/en active
- 2010-07-08 HU HUE10759940A patent/HUE027263T2/en unknown
- 2010-07-08 ME MEP-2016-66A patent/ME02443B/me unknown
- 2010-07-08 RS RS20160255A patent/RS54718B1/sr unknown
- 2010-07-08 CA CA2767291A patent/CA2767291C/en active Active
- 2010-07-08 NZ NZ597075A patent/NZ597075A/xx unknown
- 2010-07-08 SG SG2012001236A patent/SG177558A1/en unknown
- 2010-07-08 CN CN201080030894.9A patent/CN102596923B/zh active Active
- 2010-07-08 EA EA201200102A patent/EA026674B1/ru not_active IP Right Cessation
- 2010-07-08 PL PL10759940T patent/PL2451794T3/pl unknown
- 2010-07-08 BR BR112012000370-4A patent/BR112012000370B1/pt active IP Right Grant
- 2010-07-08 US US13/381,426 patent/US9162994B2/en active Active
- 2010-07-08 AU AU2010270030A patent/AU2010270030B2/en active Active
- 2010-07-08 SI SI201031157A patent/SI2451794T1/sl unknown
-
2011
- 2011-12-01 IL IL216723A patent/IL216723A/en active IP Right Grant
- 2011-12-05 ZA ZA2011/08901A patent/ZA201108901B/en unknown
-
2015
- 2015-10-14 US US14/883,190 patent/US9675596B2/en active Active
-
2016
- 2016-07-12 SM SM201600225T patent/SMT201600225B/it unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006045581A1 (en) * | 2004-10-21 | 2006-05-04 | Neuropharma, S.A. | The use of 1, 2, 4-thiadiazolidine-3, 5-diones as ppar activators |
Non-Patent Citations (1)
| Title |
|---|
| 1,3-Dipolar Cycloadditions of Alkyl Azides with Picryl Isothiocyanate: Isolation of Stable Monoadducts;Gerrit L. ET AL;《JOURNAL OF HETEROCYCLIC CHEMISTRY》;19900630;第27卷(第4期);1059-1062 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102596923B (zh) | 1,2,4-噻唑烷-3-酮衍生物及其在癌症治疗中的用途 | |
| WO2020146636A1 (en) | Compounds and methods for treating or preventing heart failure | |
| JP5216341B2 (ja) | 血管新生阻害活性を有する新規オキサジアゾール誘導体およびチアジアゾール誘導体 | |
| WO2010073011A2 (en) | Compounds useful as medicaments | |
| TW200524575A (en) | Biaryl linked hydroxamates: preparation and pharmaceutical applications | |
| WO2005103022A1 (en) | Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators | |
| CA2476406A1 (en) | Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient | |
| TW200402291A (en) | Antiallergic | |
| TW200831511A (en) | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | |
| EP2630144B1 (en) | Rho kinase inhibitors | |
| WO2019162702A1 (en) | Triazine derivatives for treating diseases relating to neurotrophins | |
| JP2020519582A (ja) | 新規なピペリジン−２，６−ジオン誘導体及びその用途 | |
| WO2010086613A1 (en) | Compounds useful as inhibitors as ampk | |
| AU2006271375A2 (en) | Use of thiazole derivatives and analogues in the treatment of cancer | |
| WO2008090356A1 (en) | Thiazolidinone derivatives useful in the treatment of cancer and disorders caused by excess adiposity | |
| TW200530206A (en) | New compounds | |
| WO2013108026A1 (en) | Thiadiazolone derivatives useful in the treatment of diabetes | |
| HK1170485B (en) | 1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer | |
| JP2003201279A (ja) | インドール化合物及びその医薬用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder |
Address after: Swedish chicken Patentee after: Betagennon Co. Address before: Swedish chicken Patentee before: BETAGENON AB |
|
| CP01 | Change in the name or title of a patent holder |